Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer
deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic …

Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …

Triple-negative breast cancer (TNBC) is an aggressive subtype associated with early
metastatic recurrence and worse patient outcomes. TNBC tumors express molecular …

Background: During a developmental process, embryos employ varying tactics to remove
unwanted cells. Using a procedure analogous to some of the embryonic cells, we generated …

Cancer stem-like cells (CSCs) represent a key barrier to successful therapy for triple-
negative breast cancer (TNBC). CSCs promote the emergence of chemoresistance …

Simple Summary Cyclin-dependent kinase inhibitors (palbociclib (Ibrance), ribociclib
(Kisqali), and abemaciclib (Verzenio)), targeting aberrant cell-cycle activity have been …

Simple Summary Triple-negative breast cancer (TNBC), the most aggressive and
heterogenous type of cancer, lacks the expression of hormones like estrogen, progesterone …

Background: Triple-negative breast cancer (TNBC), as a highly aggressive and metastatic
tumor, can still not contain the medical needs. It has become an urgent problem to develop …

Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the lack
of expression of estrogen and progesterone receptors and amplification of human epidermal …

Negative expression of the estrogen receptor, progesterone receptor, and human epidermal
growth factor receptor-2 disqualifies triple-negative breast cancer (TNBC) as a candidate for …